Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881721 | 0.89 | NOTUM (0.44) | NOTUMLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5881579 | 0.85 | NOTUM (0.41) | NOTUMPOLBKDM4EALDH1A1HPGD | |
| SCHEMBL5881634 | 0.85 | NOTUM (0.48) | NOTUMKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL5993336 | 0.77 | NOTUM (0.42) | NOTUMLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5881708 | 0.74 | POLB (0.37) | NOTUMPOLB | |
| SCHEMBL3267361 | 0.74 | NOTUM (0.53) | NOTUMKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3269563 | 0.74 | NOTUM (0.53) | NOTUMKDM4EALDH1A1HPGD | |
| SCHEMBL5993673 | 0.72 | ALDH1A1 (0.41) | NOTUMLMNAKDM4EALDH1A1HPGD | |
| SCHEMBL5881541 | 0.71 | POLB (0.35) | NOTUMPOLBMAPT | |
| SCHEMBL1761252 | 0.69 | NOTUM (0.48) | NOTUMKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012147-B2 | Enzyme inhibitors; chemical intermediates | SANKYO COMPANY, LIMITED (JP) | 2006-03-14 | — | — | US | disclosed |
| US-20060014965-A1 | Indoline derivative and process for producing the same | SANKYO COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20040058979-A1 | Indoline derivative and process for producing the same | SANKYO COMPANY, LIMITED (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1364942-A1 | INDOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Sankyo Company, Limited (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014965-A1 | Indoline derivative and process for producing the same | ACAT2, ACAT1, INMT | NOTUM 294/4885POLB 3159/4885LMNA 3850/4885 |
| US-20040058979-A1 | Indoline derivative and process for producing the same | ACAT2, ACAT1, INMT | NOTUM 294/4885POLB 3159/4885LMNA 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.